

<https://conferences.asco.org/am/program>

Cancer Center Members indicated in



[Conquer the Clot: Addressing VTE in Your Patients with Cancer](#)

Friday, June 4, 2021, 9:30 AM - 10:45 AM EDT

Faculty: (Cleveland Clinic Lerner College of Medicine), Michael Streiff, MD (Johns Hopkins University School of Medicine), Tzu-Fei Wang, MD, MPH (The University of Ottawa)



Cancer Center members indicated in BOLD

France; University of Pittsburgh Cancer Institute, Pittsburgh, PA; Mayo Clinic, Rochester, MN; Rose Ella Burkhardt Brain Tumor and Neuro-Oncology Center, Neurological Institute, Taussig

Cancer Center members indicated in BOLD

Morris, Robert I.

Cancer Center members indicated in BOLD

Cancer Center members indicated in BOLD

Cancer Center members indicated in BOLD

Cancer Institute and Cleveland Clinic, Cleveland, OH; Cleveland Clinic, Cleveland, OH; Cleveland Clinic Foundation, Cleveland, OH; Dana-Farber/Brigham and Women's Cancer Center, Harvard Medical School, Boston, MA; Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA

(2017) Superior overall survival (OS) and disease-

Cancer Center members indicated in BOLD

Cancer Center members indicated in BOLD

Medical Center, Los Angeles, CA; Moffit Cancer Center, Tampa, FL; The University of Texas MD Anderson Cancer Center, Houston, TX; H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL; Yale School of Medicine and Yale Cancer Center, New Haven, CT; The James Graham Brown Cancer Center at University of Louisville, Louisville, KY; Moores Cancer Center, La Jolla, CA; University of Alabama at Birmingham, Birmingham, AL; Emory University School of Medicine, Atlanta, GA; Case Comprehensive Cancer Center, University Hospital of Cleveland Medical Center, Cleveland, OH; Ohio State University Comprehensive Cancer Center, Columbus, OH; Stanford University, Stanford, CA

[\(7010\) Phase II study of the IDH2-inhibitor enasidenib in patients with high-risk IDH2-mutated myelodysplastic syndromes \(MDS\).](#)

Hematologic Malignancies







Cancer Center members indicated in BOLD

Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH; Cleveland Clinic, University Heights, OH; Rose Ella Burkhardt Brain Tumor and Neuro-Oncology Center, Neurological Institute, Taussig Cancer Institute and Cleveland Clinic, Cleveland, OH

[\(2032\) Outcomes of immunotherapy \(ICI\) alone vs tyrosine kinase inhibitors \(TKI\) alone versus ICI and TKI combined in renal cell carcinoma brain metastasis.](#)

Central Nervous System Tumors – Brain Metastases

Authors: Patrick Joseph O'Shea, Vineeth Tatineni, Yasmeen Rauf, Xuefei Jia, Erin Sennett Murphy,  
; Cleveland Clinic,

Cleveland, OH; Burkhardt Brain Tumor and Neuro-

[\(2061\) Safety and feasibility of rhenium-186 nanoliposome \(186RNL\) in recurrent glioma: The ReSPECT phase 1 trial.](#)

Central Nervous System Tumors – Primary CNS Tumors – Glioma

Authors: Andrew J. Brenner, Ande Bao, William Phillips, Gregory Stein, Vibhudutta Awasthi, Toral R. Patel, Jeffrey Weinberg, John Floyd; University of Texas Health San Antonio Cancer Center, San Antonio, TX; Case Western Reserve University, Cleveland, OH; UT Health San Antonio, San Antonio, TX; Plus Therapeutics, Inc., Austin, TX; University of Oklahoma Health Sciences Center, College of Pharmacy, Oklahoma City, OK; UT Southwestern Medical Center, Dallas, TX; MD Anderson Cancer Center, Houston, TX; The University of Texas Health Science Center at San Antonio, San Antonio, TX

[\(2545\) Using the tumor microenvironment to identify predictors of immunotoxicity to checkpoint inhibitors.](#)

Developmental Therapeutics—Immunotherapy – Inflammatory Signatures

Authors: William Alexander, Kristopher Attwood, Kayla Catalfamo, Grace K. Dy, Saby George, Marc S. Ernstoff, Yara Abdou; University at Buffalo, Buffalo, NY; Biostatistics, Roswell Park Comprehensive Cancer Center, Buffalo, NY; Department of Biostatistics and Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, NY; Roswell Park Comprehensive Cancer Center, Buffalo, NY; Cleveland Clinic, Cleveland, OH

[\(2552\) Selection of the recommended phase 2 dose \(RP2D\) for subcutaneous nemvaleukin alfa: ARTISTRY-2.](#)

Developmental Therapeutics—Immunotherapy – New targets and New Technologies (IO)

Authors: Omid Hamid, Stephen V. Liu, Ralph V. Boccia, Justin A Call, Trisha Michel Wise-Draper, Angela Tatiana Alistar, John D. Powderly, Bradley Curtis Carthon, Ulka N. Vaishampayan, Anthony J. Olszanski, John M. Wrangle, Anthony Frank Shields, Sarina Anne Piha-Paul, Monali Desai, MD, Yangchun Du, Lei Sun, PhD, Yan Wang, Heather Losey, Craig Hopkinson, Marc S. Ernstoff; The Angeles Clinic and Research Institute, Los Angeles, CA; Georgetown University, Department of Hematology and Oncology, School of Medicine, Washington, DC; Center for Cancer and Blood Disorders, Bethesda, MD; Utah Cancer Spclsts, Salt Lake City, UT; University of Cincinnati Cancer Center, Cincinnati, OH; Atlantic Health System, Morristown, NJ; Carolina BioOncology Institute, Huntersville, NC; Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA; University of Michigan Cancer Center, Detroit, MI; Fox Chase Cancer Center,

Cancer Center members indicated in BOLD

[\(3054\) Novel imaging biomarkers predict progression-free survival in stage 3 NSCLC treated with](#)

Cancer Center members indicated in BOLD

Center, Keck School of Medicine, Los Angeles, CA; Caris Life Sciences, Phoenix, AZ; Chiba Cancer Center, Chiba, Japan; USC Keck School of Medicine, Los Angeles, CA; Karmanos Cancer Institute, Detroit, MI; Cleveland Clinic, Cleveland, OH; Mitchell Cancer Institute, Mobile, AR; Georgetown University Hospital, Washington, DC; Fox Chase Cancer Center, Philadelphia, PA; St Jude Heritage Medcl Grp, Fullerton, CA; Karmanos Cancer Institute, Wayne State University, Detroit, MI; Washington University School of Medicine in St. Louis, St. Louis, MO; USC Norris Comprehensive Cancer Center, Los Angeles, CA; University of Minnesota School of Medicine, Minneapolis, MN

[\(3128\) The impact of clinical decision making in a molecular tumor board at a tertiary care center.](#)

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology – Tissue-Based Biomarkers

Authors: Meena Sadaps, Kathryn Demski, Ying Ni, Vicky Konig, Brandie Leach, Emily Mazzei, Pauline Funchain; Cleveland Clinic, Cleveland, OH; Genomic Medicine Institute, Cleveland Clinic Lerner Research Institute, Cleveland, OH; Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

[\(3129\) The mutational landscape of the sensitivity of cancer to ionizing radiation.](#)

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology – Tissue-Based Biomarkers

Authors: Priyanka Gopal, Brian Yard, Aaron Petty, Jessica Castrillon, Jyoti D. Patel, Mohamed E. Abazeed; Northwestern University, Chicago, IL; Cleveland Clinic, Cleveland, OH; Cleveland Clinic Foundation, Cleveland, OH; Lurie Cancer Center, Northwestern University-Feinberg School of Medicine, Chicago, IL; Northwestern University, Chicago, IL

Cancer Center members indicated in BOLD

(4131) Body composition me

Cancer Center members indicated in BOLD



Cancer Center members indicated in BOLD

OH; Hartford HealthCare Cancer Institute, Hartford, CT; Brown University Warren Alpert Medical School, Providence, RI

[\(6566\) Initial report on hospitalized cancer patients with COVID-19 from the National Cancer Institute \(NCI\) COVID-19 in Cancer Patients Study \(NCCAPS\).](#)

Health Services Research and Quality Improvement – Outcomes

Authors: Nicholas M. Mark, Ana F. Best, , Steven Pergam, Grace E. Mishkin, Melissa Bowman, Andrea M. Denicoff, Lawrence Rubinstein, Lalitha Krishna Shankar, James H. Doroshow, Brian I. Rini, Larissa A. Korde; NCCAPS Study Team; Swedish Medical Center, Seattle, WA; National Cancer Institute, Rockville, MD; Cleveland Clinic-Taussig Cancer Institute, Cleveland, OH; Fred Hutchinson Cancer Research Center, Seattle, WA; The Emmes Company, LLC, Rockville, MD; Biometric Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD; Diagnostic Imaging Branch, National Cancer Institute, Bethesda2(E)-11(. )23(M)-8(is)7(7c6)8(a)5( )4(D)4(i)8(a)7(gn)-3(

Cancer Center members indicated in BOLD

[\(7546\) Duration of response to loncastuximab tesirine in relapsed/refractory diffuse large B-cell lymphoma by demographic and clinical characteristics: Subgroup analyses from LOTIS 2.](#)  
Hematologic Malignancies—

Cancer Center members indicated in BOLD

Authors: Caron A. Jacobson, Frederick Lundry Locke, Zhen-Huan Hu, Tanya Siddiqi, Sairah Ahmed, Armin Ghobadi, David Bernard Miklos, Yi Lin, Miguel-Angel Perales, Matthew Alexander Lunning, Megan Herr, Siddhartha Ganguly, Hua Dong, Sarah Nikiforow, Jing Xie, Hairong Xu, Michele Hooper, Jun Kawashima, Marcelo C. Pasquini; Dana-Farber Cancer Institute, Boston, MA; H. Lee Moffitt Cancer Center &









Cancer Center members indicated in BOLD

Massachusetts General Hospital, Boston, MA; University of Michigan, Ann Arbor, MI; Relay Therapeutics, Cambridge, MA; The University of Texas MD Anderson Cancer Center, Houston, TX

[\(TPS4176\) A phase II open-label study of cpi-613 in combination with modified \(m\)FOLFIRINOX in patients with locally advanced pancreatic cancer.](#)

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary – Pancreatic Cancer

Authors: , Amr Mohamed, , Erin E. Anderson,

John Brian AI1HYs-11(r)4(n, )] TJETQq0.00000912 0 612 792 reW\*ñBT/F2 11 Tf1 0 161 212.25 617.7 Tm0 g0 GR:-10(i)-5(h3



Cancer Center members indicated in BOLD

[\(TPS8584\) Randomized phase III Trial of MEDI4736 \(durvalumab\) as concurrent and consolidative therapy or consolidative therapy alone for unresectable stage 3 NSCLC: A trial of the ECOG-ACRIN Cancer Research Group \(EA5181\).](#)

Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers – Local-Regional Non-Small Cell Lung Cancer



Cancer Center members indicated in BOLD

Authors: Miguel Salazar, Estefania Gauto, Shristi Upadhyay Upadhyay Banskota, Pedro Palacios, Trilok Shrivastava, Binav Baral, Pierre Alexander Rodriguez Alarcon, Maha Elsebaie, Nabin Khanal; Cleveland Clinic, Cleveland, OH; John H. Stroger Jr. Hospital of Cook County, Chicago, IL; John H. Stroger Hospital of Cook County, Chicago, IL; Mayo Clinic Jacksonville Gastroenterology & Hepatology, Jacksonville, FL; John H. Stroger, Jr. Hospital of Cook County, Chicago, IL; John H. Stroger Jr. Hospital of Cook County Internal Medicine, Chicago, IL; Creighton University School of Medicine, Omaha, NE

[\(e16193\) Predictors of 30-](#)

Cancer Center members indicated in BOLD

Authors: , Longbin Xiong, Nguyen Jane, Fangjian Zhou, Zhiling Zhang, Yulu Peng;  
Cleveland Clinic Glickman Urological and Kidney Institute, Cleveland, OH; Sun Yat-sen University Cancer Center,  
Guangzhou, China; Center for Urologic Oncology, Glickman Urological and Kidney Institute, Cleveland Clinic,  
Cleveland, OH

[\(e17033\) Real-world outcomes among prostate cancer patients with BRCA2 gene variants compared to variants in other homologous DNA repair genes.](#)

Genitourinary Cancer—Prostate, Testicular, and Penile – Prostate Cancer – Advanced/Castrate-Resistant  
Authors: Meghan Price, Vishal Vashistha, David Winski, Michael Kelley, Rhonda Bitting, Robert B.  
Montgomery; Duke University School of Medicine, Durham, NC; Cleveland Clinic Foundation, Cleveland, OH;  
Durham VA Medical Center, Durham, NC; Durham VA Health Care System, Durham, NC; Durham Veterans Affairs  
Medical Center, Durham, NC; University of Washington, Seattle, WA

[\(e17570\) A longitudinal study of the adherence to PORTEC-2 based adjuvant radiotherapy in high-intermediate-risk endometrial adenocarcinoma and associated oncologic outcomes.](#)

Gynecologic Cancer – Uterine Cancer  
Authors: Hadi Erfani, Atefeh Rezaei, Anthony Costales;



Cancer Center members indicated in BOLD



Cancer Center members indicated in BOLD

[\(e20032\) Role of adjunct plasma exchange or high cut-off hemodialysis in the management of myeloma cast nephropathy: A systematic review.](#)

Hematologic Malignancies-Plasma Cell Dyscrasia – Multiple Myeloma

Authors: Nazma Hanif, Muhammad Khawar Sana, Basel Abdelazeem, Abdul Rafae, Muhammad Umair Mushtaq, ; Foundation University Medical College, Islamabad, Pakistan; King Edward Medical University, Lahore, Pakistan; McLaren Flint Michigan State University, Flint, MI; Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS; Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

[\(e20034\) Recent updates on bispecific T-cell engager \(BiTE\) antibodies in relapsed and refractory multiple myeloma.](#)

Hematologic Malignancies—Plasma Cell Dyscrasia



Cancer Center members indicated in BOLD

[\(e20518\) Deep learning survival model on transcriptomes level in patients with non-small cell lung cancer.](#)

Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers – Biologic Correlates

Authors: Hao Yu, Li Yang, Ka-On Lam, Jian-Yue Jin, Chen Hu, Feng-Ming Spring Kong; Shenzhen Institutes of Advanced Technology, Shenzhen, China; Department of Clinical Oncology, The University of Hong Kong-Shenzhen

Cancer Center members indicated in BOLD

Authors: Michael Castro, Ansu Kumar, Himanshu Grover, Vivek Patil, Prashant Nair, Srushti P Chafekar, Rakhi Purushothaman Suseela, Samiksha Prasad, Chandan Kumar, Vishwas Joseph, Nirjhar Mundkur, Pallavi Kumari, Anusha Pampana, Vijayashree P S, Ashish Choudhary, Veena Balakrishnan, Zakir Husain, Ashokraja Balla, Naga Ganesh, Vamsidhar Velcheti;



Cancer Center members indicated in BOLD